EnVVENO Medical To Present Topline Efficacy Data Showing Clinical Improvement From VenoValve Pivotal Trial At VENOUS2024 American Venous Forum Annual Meeting

97% of VenoValve Study Patients Showing Clinical Improvement at Six Months (as Measured by the Revised Venous Clinical Severity Score (rVCSS))

74% of the Study Patients Showing Clinical Meaningful Benefit from the VenoValve at Six Months (Improvement in rVCSS of 3 or More Points)

Average rVCSS Improvement Per Patient is 8 Points, More Than Two and a Half Times the Amount Needed to Show the VenoValve's Clinically Meaningful Benefit

Company on Track to File Application Seeking VenoValve FDA Approval in Q4 2024